Variables | Discovery cohort (n = 71) | Validation cohort (n = 32) | ||||
---|---|---|---|---|---|---|
IGF(n = 48) | DGF(n = 23) | p | IGF(n = 20) | DGF(n = 12) | p | |
Donor | ||||||
 IL-2(pg/mL) | 74.23 ± 23.96 | 96.42 ± 26.46 | 0.001 | 76.22(63.25–95.64) | 97.70(89.56–113.83) | 0.003 |
 IL-4(pg/mL) | 4.55 ± 1.87 | 3.96 ± 2.17 | 0.240 |  |  |  |
 IL-6(pg/mL) | 6.04 ± 1.55 | 5.37 ± 2.12 | 0.138 |  |  |  |
 IL-10(pg/mL) | 67.33 ± 31.53 | 73.59 ± 26.19 | 0.412 |  |  |  |
 CTLA-4;CD152(pg/mL) | 137.91 ± 58.81 | 136 ± 71.36 | 0.909 |  |  |  |
 IL-35(pg/mL) | 9.08(5.22–10.43) | 9.67(5.79–10.78) | 0.632 |  |  |  |
 HMGB1(pg/mL) | 5643.15 ± 1493.09 | 5937.63 ± 1968.60 | 0.486 |  |  |  |
recipient | ||||||
 IL-2(pg/mL) | 99.62 ± 23.45 | 94.87 ± 20.93 | 0.411 |  |  |  |
 IL-4(pg/mL) | 5.95 ± 1.79 | 6.26 ± 1.19 | 0.454 |  |  |  |
 IL-6(pg/mL) | 7.65 ± 1.50 | 7.39 ± 1.41 | 0.481 |  |  |  |
 IL-10(pg/mL) | 92.76 ± 21.57 | 89.61 ± 20.24 | 0.559 |  |  |  |
 CTLA-4;CD152(pg/mL) | 214.50 ± 54.42 | 213.83 ± 50.69 | 0.961 |  |  |  |
 IL-35(pg/mL) | 11.01 ± 2.11 | 11.05 ± 2.86 | 0.944 |  |  |  |
 Treg (%) | 5.10 ± 2.39% | 5.34 ± 2.53% | 0.700 |  |  |  |